Free Trial
NASDAQ:TELO

Telomir Pharmaceuticals 5/13/2024 Earnings Report

Telomir Pharmaceuticals logo
$1.56 -0.11 (-6.59%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.59 +0.03 (+1.92%)
As of 08/8/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Telomir Pharmaceuticals EPS Results

Actual EPS
-$0.23
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Telomir Pharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Telomir Pharmaceuticals Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Telomir Pharmaceuticals' next earnings date is estimated for Tuesday, August 12, 2025, based on past reporting schedules.

Conference Call Resources

Telomir Pharmaceuticals Earnings Headlines

Telomir Flat on Trial Data Release
$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.
TELO Announces Another Important Breakthrough
See More Telomir Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Telomir Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Telomir Pharmaceuticals and other key companies, straight to your email.

About Telomir Pharmaceuticals

Telomir Pharmaceuticals (NASDAQ:TELO), a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland.

View Telomir Pharmaceuticals Profile

More Earnings Resources from MarketBeat